A detailed history of Geode Capital Management, LLC transactions in Tempest Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 220,067 shares of TPST stock, worth $189,257. This represents 0.0% of its overall portfolio holdings.

Number of Shares
220,067
Previous 154,241 42.68%
Holding current value
$189,257
Previous $337,000 8.61%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$0.96 - $2.23 $63,192 - $146,791
65,826 Added 42.68%
220,067 $308,000
Q2 2024

Aug 09, 2024

BUY
$2.01 - $5.44 $44,537 - $120,539
22,158 Added 16.78%
154,241 $337,000
Q1 2024

May 13, 2024

BUY
$3.16 - $4.66 $19,481 - $28,728
6,165 Added 4.9%
132,083 $516,000
Q4 2023

Feb 13, 2024

BUY
$0.23 - $9.77 $8,014 - $340,445
34,846 Added 38.26%
125,918 $554,000
Q3 2023

Nov 13, 2023

SELL
$0.3 - $1.39 $3,351 - $15,529
-11,172 Reduced 10.93%
91,072 $27,000
Q2 2023

Aug 11, 2023

BUY
$1.12 - $3.76 $39,616 - $132,998
35,372 Added 52.9%
102,244 $129,000
Q1 2023

May 15, 2023

SELL
$1.14 - $2.91 $498 - $1,271
-437 Reduced 0.65%
66,872 $155,000
Q4 2022

Feb 13, 2023

SELL
$1.15 - $2.12 $231 - $426
-201 Reduced 0.3%
67,309 $78,000
Q3 2022

Nov 14, 2022

BUY
$1.62 - $2.76 $67,719 - $115,373
41,802 Added 162.6%
67,510 $117,000
Q2 2022

Aug 12, 2022

SELL
$2.08 - $4.15 $18,331 - $36,573
-8,813 Reduced 25.53%
25,708 $54,000
Q1 2022

May 13, 2022

BUY
$2.27 - $5.45 $397 - $953
175 Added 0.51%
34,521 $117,000
Q4 2021

Feb 11, 2022

BUY
$5.28 - $15.2 $58,317 - $167,884
11,045 Added 47.4%
34,346 $181,000
Q3 2021

Nov 12, 2021

BUY
$10.49 - $24.19 $244,427 - $563,651
23,301 New
23,301 $337,000

Others Institutions Holding TPST

About Tempest Therapeutics, Inc.


  • Ticker TPST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 10,418,900
  • Market Cap $8.96M
  • Description
  • Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxiso...
More about TPST
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.